- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Moderna, Johnson & Johnson Booster Vaccine in Discussion and Criteria of FDA Approval
The FDA released information on booster shots for the Moderna and Johnson & Johnson COVID-19 vaccines before their public meeting that begins Thursday.
The Food and Drug Administration released information Tuesday on booster shots for the Moderna and Johnson & Johnson COVID-19 vaccines before their two-day public meeting that begins Thursday.
This news follows after the FDA's action on Pfizer-BioNTech's booster application in September. Moderna is seeking authorization of a booster dose of its vaccine on the same terms.
The Moderna booster would be for people 65 and older, those ages 18 to 64, those at high risk for severe COVID-19 and people 18 to 64 whose institutional or occupational exposure put them at risk for severe COVID-19.
Moderna's COVID-19 vaccine booster is half the dose of the initial shots used in its two-shot vaccination — 50 micrograms of mRNA versus 100 micrograms, according to documents shared by the FDA.
A Johnson & Johnson analysis shared that a booster given to those 18 and older six months or longer after initial vaccination with a single shot has more of a risk-benefit balance.
Jim Shehan, senior counsel and chair of the FDA Regulatory Practice Group of law firm Lowenstein Sandler, shared the criteria the FDA examines when evaluating the safety and need for a booster shot.
The criteria usually falls under two different categories: the safety of the product if it were to cause adverse reactions and how severe are those adverse reactions.
"Vaccines are relatively high thresholds for safety," Shehan said. "The need for an additional shot is a question of efficacy and benefit risks."
He added boosters are common. For example, people get tetanus shots every 10 years. The flu and the SARS-CoV and diseases call for a couple shots at childhood and no additional shot is needed. However, for viruses like the flu or COVID, these forms of a cold can mutate more, leading to the possibility of an additional shot.
Latest Vaccines and Antiviral Treatments Show Promising Results in Reducing Severe COVID Outcomes
March 7th 2024It was found in a recent study that the updated Moderna, Pfizer-BioNTech and Novavax COVID-19 vaccines, when combined with antiviral treatments like nirmatrelvir and molnupiravir, can significantly decrease the chances of hospitalization and death from current COVID-19 variants.
Read More
In this episode, Peter Wehrwein, managing editor of Managed Healthcare Executive, speaks with Dr. Rodrigo Cerda. Dr. Cerda has been recently promoted to the position of senior vice president of health services and chief medical officer of Independence Blue Cross in Philadelphia. He is also a member of Managed Healthcare Executive’s editorial advisory board. Peter and Dr. Cerda discuss his new role at the Independence Blue Cross, what it means to be a chief medical officer at an insurer these days, valued-based care, social determinants of health, and, of course, the pandemic.
Listen
How More Prompt Action Could Have Saved Thousands of U.S. COVID-19 Deaths
December 10th 2023Researchers of a study compared Israel's CVOID-19 booster rollout experience to the United States to ask the question: How many lives could the U.S. have saved if boosters were authorized sooner?
Read More
Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.
Listen
A Cup or Two of Joe a Day Could Keep COVID-19 Infection Away
November 19th 2023Coffee, rich in polyphenolic compounds like chlorogenic acid (CGA), caffeic acid (CAA), cafestol, melanoidins and trigonelline, has been recognized as a dominant source of CGA in various studies. Previous studies suggest that CGA in coffee can positively impact blood pressure, lipid profile, glycemia and insulin resistance.
Read More
The Challenges, Strategies of COVID-19 Misinformation Interventions
November 16th 2023COVID-19 misinformation interventions should involve public health experts, establish consistent outcome measures and more to address health misinformation at individual, community and systems levels, according researchers of a recent study.
Read More
